CA2006709C - Glucocerebrosdidase recombinant ayant une action enzymatique - Google Patents

Glucocerebrosdidase recombinant ayant une action enzymatique Download PDF

Info

Publication number: CA2006709C
Authority: CA; Canada
Prior art keywords: glucocerebrosidase; cell; human; gcr; use according
Prior art date: 1988-12-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA 2006709

Other languages

English (en)

Other versions

CA2006709A1 (fr

Inventor

James Rasmussen

Gary Barsomian

Michel Bergh

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Genzyme Corp

Original Assignee

Genzyme Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-12-23

Filing date

1989-12-27

Publication date

2001-05-22

1989-12-27 Application filed by Genzyme Corp filed Critical Genzyme Corp

1989-12-27 Priority to CA002339888A priority Critical patent/CA2339888A1/fr

1990-06-23 Publication of CA2006709A1 publication Critical patent/CA2006709A1/fr

2001-05-22 Application granted granted Critical

2001-05-22 Publication of CA2006709C publication Critical patent/CA2006709C/fr

2009-12-27 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

108010017544 Glucosylceramidase Proteins 0.000 title claims abstract description 76
102000004547 Glucosylceramidase Human genes 0.000 title claims abstract description 76
210000004027 cell Anatomy 0.000 claims abstract description 127
102000039446 nucleic acids Human genes 0.000 claims abstract description 21
108020004707 nucleic acids Proteins 0.000 claims abstract description 21
150000007523 nucleic acids Chemical class 0.000 claims abstract description 21
238000004519 manufacturing process Methods 0.000 claims abstract description 9
210000003527 eukaryotic cell Anatomy 0.000 claims abstract description 8
239000013612 plasmid Substances 0.000 claims description 39
238000000034 method Methods 0.000 claims description 37
241000282414 Homo sapiens Species 0.000 claims description 31
125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 30
210000004962 mammalian cell Anatomy 0.000 claims description 27
239000001963 growth medium Substances 0.000 claims description 18
125000000837 carbohydrate group Chemical group 0.000 claims description 17
239000002609 medium Substances 0.000 claims description 17
102000004190 Enzymes Human genes 0.000 claims description 16
108090000790 Enzymes Proteins 0.000 claims description 16
239000000203 mixture Substances 0.000 claims description 14
208000015872 Gaucher disease Diseases 0.000 claims description 13
101000576894 Homo sapiens Macrophage mannose receptor 1 Proteins 0.000 claims description 13
102100025354 Macrophage mannose receptor 1 Human genes 0.000 claims description 13
241000288906 Primates Species 0.000 claims description 13
230000027455 binding Effects 0.000 claims description 11
210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 11
UQBIAGWOJDEOMN-UHFFFAOYSA-N 2-O-(2-O-(alpha-D-mannopyranosyl)-alpha-D-mannopyranosyl)-D-mannopyranose Natural products OC1C(O)C(CO)OC(O)C1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(O)C(O)C(CO)O1 UQBIAGWOJDEOMN-UHFFFAOYSA-N 0.000 claims description 8
DINOPBPYOCMGGD-VEDJBHDQSA-N Man(a1-2)Man(a1-2)Man(a1-3)[Man(a1-2)Man(a1-3)[Man(a1-2)Man(a1-6)]Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc Chemical group O[C@@H]1[C@@H](NC(=O)C)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO[C@@H]3[C@H]([C@@H](O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)O3)O)O2)O)[C@@H](CO)O1 DINOPBPYOCMGGD-VEDJBHDQSA-N 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 5
239000003814 drug Substances 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 2
238000010253 intravenous injection Methods 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims description 2
230000003248 secreting effect Effects 0.000 claims description 2
125000003275 alpha amino acid group Chemical group 0.000 claims 10
241000699802 Cricetulus griseus Species 0.000 claims 3
210000001672 ovary Anatomy 0.000 claims 3
241000238631 Hexapoda Species 0.000 description 37
241000700605 Viruses Species 0.000 description 32
239000013598 vector Substances 0.000 description 30
108090000623 proteins and genes Proteins 0.000 description 29
108020004414 DNA Proteins 0.000 description 22
101710182846 Polyhedrin Proteins 0.000 description 20
150000002482 oligosaccharides Polymers 0.000 description 15
230000000694 effects Effects 0.000 description 14
239000012634 fragment Substances 0.000 description 13
229920001542 oligosaccharide Polymers 0.000 description 13
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 12
102000004169 proteins and genes Human genes 0.000 description 12
238000012546 transfer Methods 0.000 description 12
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical group OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 11
238000003556 assay Methods 0.000 description 10
208000015181 infectious disease Diseases 0.000 description 10
238000010367 cloning Methods 0.000 description 9
238000010276 construction Methods 0.000 description 9
238000011282 treatment Methods 0.000 description 9
238000010561 standard procedure Methods 0.000 description 8
238000001890 transfection Methods 0.000 description 8
108091003079 Bovine Serum Albumin Proteins 0.000 description 7
108091026890 Coding region Proteins 0.000 description 7
101150074155 DHFR gene Proteins 0.000 description 7
239000012894 fetal calf serum Substances 0.000 description 7
230000001105 regulatory effect Effects 0.000 description 7
239000000758 substrate Substances 0.000 description 7
102100024746 Dihydrofolate reductase Human genes 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
239000000020 Nitrocellulose Substances 0.000 description 6
230000003321 amplification Effects 0.000 description 6
108020001096 dihydrofolate reductase Proteins 0.000 description 6
229920001220 nitrocellulos Polymers 0.000 description 6
238000003199 nucleic acid amplification method Methods 0.000 description 6
YBSQGNFRWZKFMJ-UHFFFAOYSA-N Cerebroside B Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O YBSQGNFRWZKFMJ-UHFFFAOYSA-N 0.000 description 5
108020005202 Viral DNA Proteins 0.000 description 5
230000001464 adherent effect Effects 0.000 description 5
150000001413 amino acids Chemical group 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
239000000872 buffer Substances 0.000 description 5
239000006166 lysate Substances 0.000 description 5
239000011159 matrix material Substances 0.000 description 5
102000005962 receptors Human genes 0.000 description 5
108020003175 receptors Proteins 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
230000003612 virological effect Effects 0.000 description 5
241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 4
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 4
241000124008 Mammalia Species 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
150000001720 carbohydrates Chemical class 0.000 description 4
235000014633 carbohydrates Nutrition 0.000 description 4
238000012217 deletion Methods 0.000 description 4
230000037430 deletion Effects 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
239000002245 particle Substances 0.000 description 4
210000002826 placenta Anatomy 0.000 description 4
238000011160 research Methods 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
241000701447 unidentified baculovirus Species 0.000 description 4
241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
229920000936 Agarose Polymers 0.000 description 3
SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
102000004366 Glucosidases Human genes 0.000 description 3
108010056771 Glucosidases Proteins 0.000 description 3
SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 3
108010031099 Mannose Receptor Proteins 0.000 description 3
108010090665 Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase Proteins 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 3
MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
241000256251 Spodoptera frugiperda Species 0.000 description 3
108010090804 Streptavidin Proteins 0.000 description 3
229920004890 Triton X-100 Polymers 0.000 description 3
239000013504 Triton X-100 Substances 0.000 description 3
SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 3
239000013592 cell lysate Substances 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
238000012761 co-transfection Methods 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
238000001514 detection method Methods 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000013604 expression vector Substances 0.000 description 3
239000000499 gel Substances 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
238000011534 incubation Methods 0.000 description 3
210000002540 macrophage Anatomy 0.000 description 3
229910000402 monopotassium phosphate Inorganic materials 0.000 description 3
230000007935 neutral effect Effects 0.000 description 3
210000001539 phagocyte Anatomy 0.000 description 3
230000003169 placental effect Effects 0.000 description 3
230000008488 polyadenylation Effects 0.000 description 3
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
241000894007 species Species 0.000 description 3
WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 description 3
238000013519 translation Methods 0.000 description 3
210000005253 yeast cell Anatomy 0.000 description 3
HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 2
YUDPTGPSBJVHCN-YMILTQATSA-N 4-methylumbelliferyl beta-D-glucoside Chemical compound C1=CC=2C(C)=CC(=O)OC=2C=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YUDPTGPSBJVHCN-YMILTQATSA-N 0.000 description 2
101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 2
241000255789 Bombyx mori Species 0.000 description 2
108020004705 Codon Proteins 0.000 description 2
LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 description 2
229930186217 Glycolipid Natural products 0.000 description 2
241000282412 Homo Species 0.000 description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
229920000057 Mannan Polymers 0.000 description 2
108091092724 Noncoding DNA Proteins 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
108700005126 Ornithine decarboxylases Proteins 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
108091081024 Start codon Proteins 0.000 description 2
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
229960000723 ampicillin Drugs 0.000 description 2
238000013459 approach Methods 0.000 description 2
108091006004 biotinylated proteins Proteins 0.000 description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
230000000368 destabilizing effect Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
238000010828 elution Methods 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
230000012010 growth Effects 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
238000002372 labelling Methods 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
210000003712 lysosome Anatomy 0.000 description 2
230000001868 lysosomic effect Effects 0.000 description 2
238000002844 melting Methods 0.000 description 2
229960000485 methotrexate Drugs 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
239000002574 poison Substances 0.000 description 2
231100000614 poison Toxicity 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
230000006798 recombination Effects 0.000 description 2
238000005215 recombination Methods 0.000 description 2
SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
LXBIFEVIBLOUGU-KVTDHHQDSA-N (2r,3r,4r,5r)-2-(hydroxymethyl)piperidine-3,4,5-triol Chemical compound OC[C@H]1NC[C@@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-KVTDHHQDSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
YUDPTGPSBJVHCN-JZYAIQKZSA-N 4-Methylumbelliferyl-alpha-D-glucopyranoside Chemical compound C1=CC=2C(C)=CC(=O)OC=2C=C1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YUDPTGPSBJVHCN-JZYAIQKZSA-N 0.000 description 1
102000055025 Adenosine deaminases Human genes 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
206010003497 Asphyxia Diseases 0.000 description 1
241000182988 Assa Species 0.000 description 1
206010051728 Bone erosion Diseases 0.000 description 1
206010006002 Bone pain Diseases 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
JDVVGAQPNNXQDW-WCMLQCRESA-N Castanospermine Natural products O[C@H]1[C@@H](O)[C@H]2[C@@H](O)CCN2C[C@H]1O JDVVGAQPNNXQDW-WCMLQCRESA-N 0.000 description 1
JDVVGAQPNNXQDW-TVNFTVLESA-N Castinospermine Chemical compound C1[C@H](O)[C@@H](O)[C@H](O)[C@H]2[C@@H](O)CCN21 JDVVGAQPNNXQDW-TVNFTVLESA-N 0.000 description 1
108091036055 CccDNA Proteins 0.000 description 1
108020004638 Circular DNA Proteins 0.000 description 1
208000003322 Coinfection Diseases 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
230000007023 DNA restriction-modification system Effects 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
KUYCTNQKTFGPMI-SXHURMOUSA-N Glc(a1-2)Glc(a1-3)Glc(a1-3)Man(a1-2)Man(a1-2)Man(a1-3)[Man(a1-2)Man(a1-3)[Man(a1-2)Man(a1-6)]Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc Chemical compound O[C@@H]1[C@@H](NC(=O)C)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@@H](O[C@@H]4[C@@H]([C@@H](O[C@@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO[C@@H]3[C@H]([C@@H](O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)O3)O)O2)O)[C@@H](CO)O1 KUYCTNQKTFGPMI-SXHURMOUSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102000005744 Glycoside Hydrolases Human genes 0.000 description 1
108010031186 Glycoside Hydrolases Proteins 0.000 description 1
241000258937 Hemiptera Species 0.000 description 1
206010019842 Hepatomegaly Diseases 0.000 description 1
229920000209 Hexadimethrine bromide Polymers 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
208000015439 Lysosomal storage disease Diseases 0.000 description 1
VEJMLLWTNKQWKM-SHYLFXLQSA-N Man3GlcNAc Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]3O)[C@@H](O)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]3O)[C@@H]2O)[C@@H]1O VEJMLLWTNKQWKM-SHYLFXLQSA-N 0.000 description 1
ZTOKCBJDEGPICW-UHFFFAOYSA-N Man3GlcNAc2 Natural products OC1C(NC(=O)C)C(O)OC(CO)C1OC1C(NC(C)=O)C(O)C(OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(COC3C(C(O)C(O)C(CO)O3)O)O2)O)C(CO)O1 ZTOKCBJDEGPICW-UHFFFAOYSA-N 0.000 description 1
102000001696 Mannosidases Human genes 0.000 description 1
108010054377 Mannosidases Proteins 0.000 description 1
108010086093 Mung Bean Nuclease Proteins 0.000 description 1
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical group CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
SQVRNKJHWKZAKO-LUWBGTNYSA-N N-acetylneuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-LUWBGTNYSA-N 0.000 description 1
AAKDPDFZMNYDLR-UHFFFAOYSA-N N-methyl deoxynojirimycin Natural products CN1CC(O)C(O)C(O)C1CO AAKDPDFZMNYDLR-UHFFFAOYSA-N 0.000 description 1
AAKDPDFZMNYDLR-XZBKPIIZSA-N N-methyl-1-deoxynojirimycin Chemical compound CN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO AAKDPDFZMNYDLR-XZBKPIIZSA-N 0.000 description 1
102000005348 Neuraminidase Human genes 0.000 description 1
108010006232 Neuraminidase Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 1
108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 1
206010035148 Plague Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
108020005091 Replication Origin Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
206010041660 Splenomegaly Diseases 0.000 description 1
241000256248 Spodoptera Species 0.000 description 1
241000255993 Trichoplusia ni Species 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
241000607479 Yersinia pestis Species 0.000 description 1
HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
ZTOKCBJDEGPICW-GWPISINRSA-N alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc Chemical compound O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)O2)O)[C@@H](CO)O1 ZTOKCBJDEGPICW-GWPISINRSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000011210 chromatographic step Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
238000004891 communication Methods 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
238000012258 culturing Methods 0.000 description 1
230000034994 death Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
229940009976 deoxycholate Drugs 0.000 description 1
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
239000005549 deoxyribonucleoside Substances 0.000 description 1
230000008021 deposition Effects 0.000 description 1
239000010432 diamond Substances 0.000 description 1
235000018823 dietary intake Nutrition 0.000 description 1
230000029087 digestion Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
229910001651 emery Inorganic materials 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
238000007824 enzymatic assay Methods 0.000 description 1
230000007071 enzymatic hydrolysis Effects 0.000 description 1
238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
238000002641 enzyme replacement therapy Methods 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
108010052305 exodeoxyribonuclease III Proteins 0.000 description 1
230000004927 fusion Effects 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
210000000087 hemolymph Anatomy 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
238000010324 immunological assay Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000001524 infective effect Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
210000001865 kupffer cell Anatomy 0.000 description 1
101150066555 lacZ gene Proteins 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
230000002132 lysosomal effect Effects 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
229940060155 neuac Drugs 0.000 description 1
CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
238000005457 optimization Methods 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
210000003200 peritoneal cavity Anatomy 0.000 description 1
210000003024 peritoneal macrophage Anatomy 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
210000001938 protoplast Anatomy 0.000 description 1
238000011002 quantification Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
239000002342 ribonucleoside Substances 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
239000006152 selective media Substances 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
125000005629 sialic acid group Chemical group 0.000 description 1
230000009450 sialylation Effects 0.000 description 1
239000002356 single layer Substances 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
239000002904 solvent Substances 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
238000010911 splenectomy Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000012916 structural analysis Methods 0.000 description 1
238000004114 suspension culture Methods 0.000 description 1
FXUAIOOAOAVCGD-UHFFFAOYSA-N swainsonine Natural products C1CCC(O)C2C(O)C(O)CN21 FXUAIOOAOAVCGD-UHFFFAOYSA-N 0.000 description 1
FXUAIOOAOAVCGD-FKSUSPILSA-N swainsonine Chemical compound C1CC[C@H](O)[C@H]2[C@H](O)[C@H](O)CN21 FXUAIOOAOAVCGD-FKSUSPILSA-N 0.000 description 1
229960005566 swainsonine Drugs 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000008685 targeting Effects 0.000 description 1
DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
229910052722 tritium Inorganic materials 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
238000001262 western blot Methods 0.000 description 1

Landscapes

Preparation Of Compounds By Using Micro-Organisms (AREA)
Enzymes And Modification Thereof (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

CA 2006709 1988-12-23 1989-12-27 Glucocerebrosdidase recombinant ayant une action enzymatique Expired - Lifetime CA2006709C (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA002339888A CA2339888A1 (fr)	1988-12-23	1989-12-27	Glucocerebrosdidase recombinant ayant une action enzymatique

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US28958988A	1988-12-23	1988-12-23
US45550789A	1989-12-22	1989-12-22
US07/455,507		1989-12-22

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002339888A Division CA2339888A1 (fr)	1988-12-23	1989-12-27	Glucocerebrosdidase recombinant ayant une action enzymatique

Publications (2)

Publication Number	Publication Date
CA2006709A1 CA2006709A1 (fr)	1990-06-23
CA2006709C true CA2006709C (fr)	2001-05-22

Family

ID=26965721

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2006709 Expired - Lifetime CA2006709C (fr)	1988-12-23	1989-12-27	Glucocerebrosdidase recombinant ayant une action enzymatique

Country Status (1)

Country	Link
CA (1)	CA2006709C (fr)

1989
- 1989-12-27 CA CA 2006709 patent/CA2006709C/fr not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2006709A1 (fr)	1990-06-23

Legal Events

Date	Code	Title	Description
1993-07-12	EEER	Examination request
2009-12-27	MKEX	Expiry

Publication	Publication Date	Title
US5236838A (en)	1993-08-17	Enzymatically active recombinant glucocerebrosidase
US6451600B1 (en)	2002-09-17	Enzymatically active recombinant glucocerebrosidase
WO1990007573A1 (fr)	1990-07-12	Glucosyl-ceramidase de recombinaison a action enzymatique
US11649474B2 (en)	2023-05-16	Method for producing glycoprotein having mannose residue as non-reducing end of sugar chain
JP4005629B2 (ja)	2007-11-07	生物学的に活性なα−ガラクトシダーゼＡのクローニング及び発現
US5549892A (en)	1996-08-27	Enhanced in vivo uptake of glucocerebrosidase
Wagner et al.	1996	Elongation of the N-glycans of fowl plague virus hemagglutinin expressed in Spodoptera frugiperda (Sf9) cells by coexpression of human β1, 2-N-acetylglucosaminyltransferase I
Grace et al.	1990	Human acid β-glucosidase: glycosylation is required for catalytic activity
Hiroi et al.	1998	Molecular cloning of human homolog of yeast GAA1 which is required for attachment of glycosylphosphatidylinositols to proteins 1
CA1340829C (fr)	1999-11-23	Adn clone pour la synthese d'une glucocerebrosidase originale
Bartelsen et al.	1998	Expression of recombinant human acid sphingomyelinase in insect Sf21 cells: purification, processing and enzymatic characterization
US20030215435A1 (en)	2003-11-20	Expression system for effeiciently producing clinically effective lysosomal enzymes (glucocerebrosidase)
Bergh et al.	1987	Expression of the Saccharomyces cerevisiae glycoprotein invertase in mouse fibroblasts: glycosylation, secretion, and enzymatic activity.
CA2006709C (fr)	2001-05-22	Glucocerebrosdidase recombinant ayant une action enzymatique
US20020168750A1 (en)	2002-11-14	Enzymatically active recombinant glucocerebrosidase
Grabowski et al.	1989	Expression of functional human acid ß-glucosidase in COS-1 and Spodoptera frugiperda cells
CA2339888A1 (fr)	1990-06-23	Glucocerebrosdidase recombinant ayant une action enzymatique
Chawla et al.	1995	Secretion of active human lecithin-cholesterol acyltransferase by insect cells infected with a recombinant baculovirus
Marchal et al.	2001	Expression of a membrane-bound form of Trypanosoma cruzi trans-sialidase in baculovirus-infected insect cells: a potential tool for sialylation of glycoproteins produced in the baculovirus–insect cells system
AU7639294A (en)	1995-03-27	Recombinant alpha-galactosidase enzyme and cdna encoding said enzyme
AU4772596A (en)	1996-08-21	Recombinant alpha-galactosidase enzyme
Farrell	1999	The development of stably transformed lepidopteran insect cell technology for both the expression of recombinant proteins and the generation of baculovirus artificial chromosomes.
Breitbach	2000	Extending the N-glycosylation pathway of an insect cell line derived from Trichoplusia ni